Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Penumbra Place ALAMEDA CA 94502 |
Tel: | N/A |
Website: | https://www.penumbrainc.com |
IR: | See website |
Key People | ||
Adam Elsesser Chairman of the Board, President, Chief Executive Officer | Maggie S. Yuen Chief Financial Officer | Johanna Roberts Executive Vice President, General Counsel, Secretary | Lambert Shiu Chief Accounting Officer |
Business Overview |
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets. |
Financial Overview |
For the nine months ended 30 September 2024, Penumbra Inc revenues increased 14% to $879.1M. Net loss totaled $19.7M vs. income of $36.7M. Revenues reflect Vascular segment increase of 27% to $595.3M, United States segment increase of 18% to $654.2M, International segment increase of 2% to $224.9M. Net loss reflects Sales, General and Administrative -Other increase of 16% to $395.3M (expense). |
Employees: | 4,200 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $9,024M as of Sep 30, 2024 |
Annual revenue (TTM): | $1,164M as of Sep 30, 2024 |
EBITDA (TTM): | $143.16M as of Sep 30, 2024 |
Net annual income (TTM): | $34.55M as of Sep 30, 2024 |
Free cash flow (TTM): | $134.18M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 38,379,199 as of Oct 16, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |